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Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
Grand Forks, ND 58202-9037

Abstract

Literature Review

Discussion

Applicability to Clinical Practice

There is a strong established relationship between diabetes and
cardiovascular disease. Much of the latest research studies have
identified a link between the inflammatory processes and the
pathogenesis of both cardiovascular disease and diabetes. Specific
inflammatory markers include: Interleukins 1,6,18; C-reactive
protein, Fibrinogen, Tumor Necrosis Factor-α , PAI-I and cell
adhesion molecules. As a result, there has been an emphasis on
identifying therapeutic approaches that would improve both
markers of inflammation and glucose control. The endocrine
hormones known as incretins, glucagon-like peptide-1 (GLP-1) and
glucose-dependent insulinotropic polypeptide (GIP), are produced
in the gastrointestinal tract following ingestion of a meal. In
individuals with type 2 diabetes, endothelial dysfunction associated
with premature atherosclerosis has been well documented. The
purpose of this paper is to determine whether increasing levels of
GLP-1 reduce markers of inflammation while improving both
glucose control and cardiovascular risk factors. The review of
literature explored the impact of increasing GLP-1, either though
DPP-IV inhibitors or GLP-1 analogues, on various inflammatory
markers in patients with type 2 diabetes. The studies reviewed
provided ample support for the use of DPP-IV inhibitors to improve
both glycemic control and cardiovascular risk factors. GLP-1
analogues also appear to have a similar impact, but with the added
benefit of weight loss. In addition, patients with type 2 diabetes
frequently have coagulation abnormalities leading to a
prothrombotic state. Thus the reduction in fibrinogen, C-reactive
protein and plasminogen activator inhibitor observed during the
review of literature supports the potential for DPP-IV inhibitors and
GLP-1 agonists to exhibits an antithrombotic effect. These findings
are of clinical significance as these treatments may potentially slow
the progression of premature cardiovascular disease as well as
reduce thrombotic events in patients with type 2 diabetes.

• An article search of the following electronic medical databases
was conducted; PubMed, The Cochran Library, DynaMed and
MEDLINE. A combination of keywords and subject headings
were used, with search terms including: type 2 diabetes, DPPIV inhibitors, GLP-1 agonist, incretins, inflammation,
cardiovascular disease.
• Full articles were retrieved for further review if the information
given suggested that the study: included patients with type two
diabetes mellitus, measured pre and post markers of
inflammation, cardiovascular risk factors or changes in glucose
following either a DPP-IV inhibitor or a GLP-1 agonist active
intervention.

• Based on the studies discussed, DPP-IV inhibitors have been
shown to improve glycemic control and, based on the small trials,
appear to have great potential to provide beneficial cardiovascular
effects due to their positive impact on reducing inflammatory
markers.
• GLP-1 agonists also appear to have similar benefits as DPP-IV
inhibitors with the added benefit of weight loss. In addition,
patients with type 2 diabetes frequently have coagulation
abnormalities leading to a prothrombotic state. Thus the
reduction in fibrinogen, C-reactive protein and plasminogen
activator inhibitor observed during the review of literature
supports the potential of DPP-IV inhibitors and GLP-1 agonists
having an antithrombotic effect.

• The findings of this research project are applicable to several
areas of clinical practice. The literature supports the antiinflammatory effect of both DPP-IV inhibitors and GLP-1. While
these pharmacologic therapies have been on the market for over a
decade, there utilization is not optimized.
• Given the minimal risk of hypoglycemia associated side effects
with both DPP-IV inhibitors and GLP-1 analogs, as well as their
impact on HgbA1c reduction, it seems most appropriate for there
to be a shift in the prescribing habits of clinicians as they work
with patients to help achieve improved glycemic control.

Introduction
The relationship between diabetes and cardiovascular disease has
been the focus of many empirical investigations. Across time,
researchers have explored a link between inflammatory processes
and the pathogenesis of both diabetes and cardiovascular disease.
Consequently, there has been an emphasis on identifying
therapeutic approaches that would improve both markers of
inflammation and glucose control; thereby slowing the progression
of premature cardiovascular disease in patients with type 2
diabetes. The purpose of this review is to examine the role of
increased levels of GLP-1 in reducing markers of inflammation.

Statement of the Problem
Given the known relationship between diabetes, premature
cardiovascular disease and the inflammatory involvement; it is
important to explore inflammatory markers and therapies that may
reduce their negative impact on endothelial function.

Research Question
In patients with type 2 diabetes, does increasing GLP reduce
markers of inflammation, while improving both glucose control
and cardiovascular risk factors.

• Tremblay et al. 2014 conducted a double blinded, cross over
study using Sitagliptin (Januvia) or placebo. Thirty men and six
postmenopausal women, (who were not receiving HRT), with
type 2 diabetes participated in the study. Mean age and BMI,
58.1 and 30.7, respectively. The treatment with 100mg of
Sitagliptin significantly reduced the levels of CRP, IL-6 and IL18 by -44.9% (P = 0.006), -24.7% (P = 0.04) and -7.3% (P =
0.004), respectively. Additional findings included a significant
inverse correlation between changes in GLP-1 and changes in
CRP levels (r = 0.41, P = 0.01) with Sitagliptin therapy vs
placebo. In the fasting state, Sitagliptin led to significant
reductions in plasma cholesterol (-5.1%, P = 0.001). apoB (4.7%, P = 0.003), and LDL-C (-5.2%, P = 0.003) without
affecting plasma levels of triglycerides, free fatty acids and
HDL-C when compared to placebo.
• In a 12 week single center, randomized placebo controlled
double blinded prospective study, Makdissi et al. 2012, enrolled
22 obese subjects with type 2 diabetes with hemoglobin A1c
between 7.5% and 9%. None of the subjects had any
micro/macrovascular complications of diabetes. Subjects were
randomized to receive either Sitagliptin 100mg (N = 12; 6 male
and 6 female) or placebo (N = 10). Results showed fasting
GLP-1 concentrations increased 63% ± 20% (from 9.1 ± 2.8 to
15.8 ± 4.0) at 12 weeks. A significant reduction in plasma
concentrations of CRP and IL-6 by 24 ± 7 and 24 ± 8%,
respectively (P <0.05) in the Sitagliptin treated group. HgbA1c
fell significantly from 7.6 ± 0.1 to 6.9 ± 0.3% (P < 0.01), serum
triglycerides decreased from 209 ± 20 to 159±19mg/dl. There
was no significant changes in BMI, blood pressure or
cholesterol concentrations in either the treatment or placebo
groups.
• Pettigrew, et al. assessed the effect of Liraglutide on biomarkers
for cardiovascular risk in patients with type 2 diabetes. The
researchers randomized 165 patients with type 2 diabetes to
either a placebo or 0.65mg. 1.25mg or 1.9mg of Liraglutide for
14 weeks. Pre and post measurements of hsCRP, IL-6, TNF-α
and plasminogen activator inhibitor (PAI-1) and B-type
natriuretic peptide (BNP) were measured. Results showed a
significant decrease between baseline levels of PAI-1 and BNP
levels following higher dose treatment (1.25mg and 1.90mg) of
Liraglutide,( -29%; P = 0.018 and -25%; P = 0.045,
respectively. There was a non-significant, but dose dependent
reduction in hsCRP; (0.65mg = -3%; P = 0.85; 1.25mg = -12%;
P=0.46; 1.90mg = -20%; P = 0.22).

• A decrease in HgbA1c, inflammatory markers (e.g. CRP, TNF-α),
Free Fatty Acids and Triglycerides were common themes
presented during the review of literature looking specifically at
the role of DPP-IV inhibitors and their impact on increasing
GLP-1.
• DPP-IV inhibitors have been shown to be well tolerated, weight
neutral and less expensive. They do, however have less of an
impact on A1c as compared to the GLP-1 analogues.
• A common theme found with GLP-1 analogues, as seen with
DPP-IV inhibitors, is the reduction in the inflammatory markers
independent of changes in weight. Oxidative stress as measured
by PGF2α, was found to also decrease with the addition of a
GLP-1 analogue.
• Hypoglycemic events were essentially non-existent with DPP-IV
inhibitors and GLP-1 analogues.

• Both of these classes of therapy have been shown to reduce
markers of inflammation, which shows promise in reducing the
progression of cardiovascular disease and possibly thrombotic
events.
• Clinicians will be assisting patients with not only managing
glucose with anti-diabetes medications, but also cardiovascular
risk factors. Lifestyle modification, albeit challenging for
patients to embrace and sustain, is part of the practice guidelines
regardless of where the patient falls in the algorithm and should
remain part of the treatment plan.
• Clinicians should be working with patients to enhance
management of all comorbidities associated with diabetes,
especially cardiovascular. It seems reasonable to select diabetes
medications that will target both chronic diseases. There are oral
medications on the market that have combined DPP-IV inhibitors
with metformin.
• Clinicians need to be current and relevant in both medical and
pharmacologic knowledge, which impacts their prescribing habits
and quality of patient care.
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